Answers are grounded in this paper and cite their sources.
Background Epithelial ovarian cancer (EOC) has a poor prognosis, largely because of recurrence and platinum resistance. HOXA10, a HOX family transcription factor, has been implicated in cancer progression and chemoresistance, but its role in platinum-resistant EOC remains unclear. Methods Transcriptomic sequencing was used to identify differentially expressed genes between platinum-resistant and platinum-sensitive EOC tissues. HOXA10 expression and its associations with cisplatin responsiveness, malignant phenotypes, and epithelial–mesenchymal transition (EMT) were evaluated in clinical specimens and ovarian cancer cell models. A nude mouse xenograft model was used for in vivo validation. Public transcriptomic datasets and enrichment analyses were further used to explore HOXA10-associated pathways and tumor immune microenvironment features. Results HOXA10 expression was reduced in platinum-resistant EOC tissues and A2780/DDP cells and was associated with EMT-related changes. In an exploratory cohort of 31 patients with HGSOC, higher HOXA10 expression was associated with lower odds of platinum resistance after adjustment for age (adjusted OR = 0.399 per 0.1-unit increase, 95% CI: 0.198–0.804, P = 0.010). HOXA10 overexpression suppressed proliferation, migration, invasion, and EMT-associated phenotypes in A2780/DDP cells. Moreover, HOXA10 overexpression reduced the cisplatin IC 50 and enhanced cisplatin-mediated inhibition of clonogenic growth and wound closure. In vivo , HOXA10 overexpression was associated with reduced xenograft growth, with the lowest tumor burden observed in the combined-treatment group. Single-cell transcriptomic analysis and tissue immunofluorescence further indicated associations between HOXA10 expression, immune-cell composition, and PD-L1 expression. Conclusion Lower HOXA10 expression was associated with platinum-resistant status in EOC, while experimental findings suggested a role for HOXA10 in regulating malignant phenotypes and cisplatin responsiveness. However, the small clinical cohort and limited covariate adjustment preclude conclusions regarding its independent predictive value. Larger independent cohorts and further mechanistic studies are needed to establish its clinical and biological significance.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: